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Osteopontin (OPN), also known as early T-lymphocyte activation 1(Eta-1) 
that is encoded by the Spp-1 gene, is a phosphorylated acidic glycoprotein 
initially identified in 1979 (1,2). Senger et al. described it as a secreted 
protein associated with neoplastic transformation of epithelial and 
fibroblastic cells (3). Independently of this, Franzen and Heinegard (4) 
isolated a 44-kDa phosphorylated glycoprotein from mineralized rat bone 
matrix, which contains an Arg–Gly–Asp (RGD) cell-binding sequence (5) 
and was named osteopontin.  
It is present in many tissues and body ﬂuids (6,7), being produced by 
various cells, such as osteoblasts, macrophages, dendritic cells, natural killer 
cells, T and B cells, epithelial cells and vascular smooth muscle cells (8). 
OPN is a secreted adhesive molecule, and it is thought to aid in the 
recruitment of monocytes-macrophages and to regulate cytokine production 
in macrophages, dendritic cells, and T-cells. OPN modulates the 
inflammatory response at several levels, from immune cell accumulation to 
activation of T helper 1 (Th1) cytokines and cell survival, thus exacerbating 
the chronic inflammatory response (9). Besides proinflammatory functions, 
physiologically OPN is a potent inhibitor of mineralization, it prevents 
ectopic calcium deposits and is a potent inducible inhibitor of vascular 
calcification (10). 
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The diverse biological functions of OPN can be explained by its different 
conserved sequence motifs some of which only become accessible if the 
protein is cleaved by thrombin. OPN contains three possible thrombin 
cleavage sites: the Arg–Gly in the RGD tripeptide and two Arg–Ser-sites at 
residues 154–155 and 158–159. OPN functions through binding to several 
receptors (11). This binding can be RGD-dependent mediated by αv and β1 
integrin subfamilies as well as RGD-independent by CD44 isoforms 
containing CD44v6-v10 (12,13). At several sites, the OPN molecule can 
additionally be cleaved by matrix metalloproteinases (MMP) (14). The fact 
that OPN interacts with multiple cell surface receptors which are 
ubiquitously expressed makes it an active player in many physiological and 
pathological processes (15). OPN is highly expressed in inflammatory cells 
associated with many diseases including cancer (16), arterial restenosis (17), 
renal tubulointerstitial fibrosis (18),  myocardial infarction, stroke (19), 
wound healing (20) , and in several chronic inflammatory diseases such as 
experimental autoimmune encephalitis, rheumatoid arthritis (21), and in a 
number of granulomatous diseases including sarcoidosis, foreign body 
granulomas, and tuberculosis (22). 
Psoriasis is a chronic disease that affects 1-3% of the population (23). It is 
an immune-mediated inflammatory disorder, where Th1 and Th17 
lymphocytes contribute to the pathogenesis through the release of 
inflammatory cytokines that promote further recruitment of immune cells, 
keratinocyte proliferation and sustained inflammation (24). Tumor necrosis 
factor alpha (TNF-α) is a pleiotropic cytokine with a central role in the 
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pathogenesis of psoriasis. Biological therapy based on monoclonal 
antibodies against TNF-α has been proven to be effective in patients with 
psoriatic arthritis on both the arthropaty and the cutaneous symptoms of the 
disease (25,26). Today there are three main biological agents targeting TNF-
α, which are already in use for treating PsA. These are the chimeric 
monoclonal IgG1 antibody infliximab with human constant and murine 
variable regions, the fully human anti-TNF-α monoclonal antibody 
adalimumab and the recombinant 75-kDa TNF-α receptor IgG1 fusion 
protein etanercept (27). Infliximab and adalimumab bind to cell membrane 
bound TNF-α, which may lead to cell lysis. Among the multiple effects 
produced by TNF-α on keratinocytes, the induction of matrix MMP-9, a 
collagenase implicated in joint inflammatory arthritis which acts as an 
angiogenesis promoting factor, might represent a key mechanism in the 
pathogenesis of the disease (28). It has been shown that OPN modulates the 
expression and/or activity of proteins that regulate extracellular matrix 
remodeling. For example, OPN has been reported to increase the migration 
and expression of MMP-9 in human chondrosarcoma cells (29) as well as in 
cardiac and skeletal muscle (30).  
We have previously showed that OPN is increased in psoriasis at peripheral 
blood mononuclear cells (PBMC) level and in skin (31). Chen et al. 
reported that high plasma OPN levels were an unfavourable factor for 
development of cardiovascular disease in patients with psoriasis (32). 
Furthermore high plasma OPN and low plasma selenium levels have been 
described as predictable factors for occurrence of psoriasis (33).  
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Aim of the present study was to investigate the relationship between OPN, 
MMP-9 and TNF-α in psoriasis, by assessing the presence of OPN and 
MMP-9 in PBMC and sera of psoriatic patients before and after anti-TNF-α 
treatment. 
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Materials and methods 
 
The study was conducted after written informed consent was obtained from 
all participants. From June 2010 to June 2011, 7 moderate-to-severe plaque 
psoriatic subjects, candidates to TNF-α antagonists, were enrolled. Before 
entering the study all subjects underwent a wash-out period of 8 weeks for 
systemic active drugs for psoriasis. Of the 7 patients enrolled, 3 were treated 
with etanercept, and four with adalimumab. Etanercept was administered 
subcutaneously 50 mg twice weekly for 12 weeks and 50 mg once weekly 
for other 12 weeks, whereas adalimumab 80 mg at week 0, followed by 40 
mg every other week for 24 weeks, subcutaneously as well. Clinical 
parameters including age, sex, body weight, phenotype of psoriasis, 
psoriasis severity, presence of psoriatic arthritis were collected. Exclusion 
criteria included known cardiovascular disorders, diabetes and active 
malignancy. Psoriasis Area and Severity Index (PASI) was used to assess 
severity of psoriasis and a score >10 was considered as moderate-to-severe 
psoriasis.  
Blood samples were taken at baseline (T0) and after 24 weeks (T1). Control 
blood samples were obtained from 10 age- and sex-matched healthy 
subjects. Ficoll-Hypaque (Biochrom Ag, Berlin 
Deutschland) density gradient centrifugations were carried out to isolate 
PBMC following manufacturer’s instructions.  
Total RNA, isolated by High Pure RNA Isolation Kit (Roche Diagnostics, 
Basel, Switzerland) from 1x106 PBMC was transcribed by reverse 
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transcriptase (Expand Reverse Transcriptase, Roche Diagnostics, Basel, 
Switzerland) at 42°C for 45 min according to the manufacturer’s 
instructions. Two µl of complementary DNA (cDNA) were amplified in a 
reaction mixture containing 10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 50 
mM KCl, 200 µM dNTP, and 2.5 units of Taq DNA polymerase (Roche 
Diagnostics) in a final volume of 50 µl. For the co-ampliflication of MMP-
9, the PCR was carried out in the presence of 0.5 µM sense and antisense 
MMP-9 primers, and 0.05 µM sense and antisense glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or β-actin primers. OPN PCR was 
carried out in the presence of 0.5 µM sense and antisense OPN primers. RT-
PCR was performed in a thermal cycler (Mastercycler gradient, Eppendorf, 
Hamburg, Germany). GAPDH or β-actin were used as housekeeping genes. 
PCR products were analyzed by electrophoresis on 1.8% agarose 
(Eppendorf, Hamburg, Germany) gel in Tris-Borate–EDTA buffer (TBE) 
(Fluka, BioChemiKa, Buchs, Switzerland). In Table 1 all sequences are 
summarized. Densitometric analysis of ethidium-bromide stained agarose 
gel was carried out by Quantity One 4.6.8 1-D Analyses Software (Bio-Rad 
Laboratories, Berkeley, CA, USA). The ratio between the yield of each 
amplified product and that of co-amplified internal control allowed a 
relative estimate of mRNA levels in the sample analyzed. 
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OPN concentration in patients' plasma was measured by ELISA assay 
(Quantikine; R&D System, Abingdon, UK) according to the manufacturer’s 
instructions. The lower limit of detection for both assays was 0.313 ng/ml. 
Measurements were performed in duplicate. Samples with a coefficient of 
variation >10% were repeated. 
 
Statistical analysis 
Paired t-test analysis of variance (ANOVA) was used to statistically analyze 
OPN plasmatic levels and gene expression levels of OPN and MMP-9 
before and after treatment. A	  P	  value	  <0.05	  was	  considered	  as	  statistically	  significant.	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GENE FORWARD PRIMER 
5’-3’ 
 REVERSE PRIMER 
5’-3’ 
B-Actin 5’-TgAcggggTCACCCACACTgTgCCCATCTA-3’ 
 
5- CTAgAAgCATTAgCggTggACgATggAggg-
3’ 
GAPDH 5’ CGGAGTCAACGGATTTGGTCGTAT-3’ 5’ AGCCTTCTCCATGGTGGTGAAGAC-3’ 
 
OPN 5’ CCAAGTAAGTCCAACGAAAG-3’ 
 
5’ GGTGATGCTCTCGTCTGTA-3’ 
MMP9 5’ ACGACGTCTTCCAGTACCGA -3’ 
 
5’ TTGGTCCACCTGGTTCAACT -3’ 
 
Table 1. Human primers sense and antisense sequences 	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Results	  
	  
A total of 7 psoriatic subjects and 10 healthy volunteers was enrolled. All 
patients completed the study. There were no significant differences in age 
and sex between the two groups. None of psoriatic patients was affected by 
arthropathy too. After	   24	   weeks	   of	   therapy	   (T1)	   5	   out	   of	   7	   patients	   reached	   PASI	   75	  (improvement	   of	   75%	   of	   PASI	   score),	   whereas	   the	   remaining	   2	  achieved	  PASI	  50.	  Psoriatic	  subjects	  showed	  significant	  higher	  levels	  of	  OPN	  expression,	  respect	  to	  healthy	  controls	  at	  baseline.	  After	  24	  weeks	  of	   TNF-­‐α	   antagonists	   all	   subjects	   showed	   a	   strong	   reduction	   of	   OPN	  gene	  expression	  reaching	  comparable	  levels	  as	  controls	  (P	  <0.001)	  (Fig.	  1).	   No	   difference	  was	   detected	   between	   the	   2	   anti-­‐TNF-­‐α	   drugs	   (data	  not	   shown).	   In	   order	   to	   evaluate	   OPN	   release,	   ELISA	   assay	   was	  performed	   on	   plasma	   blood	   samples	   of	   healthy	   donors	   and	   psoriatic	  patients	   before	   and	   after	   treatment.	   OPN	   plasma	   levels	   were	   highly	  increased	   in	  psoriatic	  subjects	  respect	   to	  healthy	  controls	   (P	  <	  0.001).	  As	  showed	  in	  Fig.	  2	  OPN	  plasma	  levels	  were	  strongly	  reduced	  after	  anti-­‐TNF-­‐α	  drugs,	  resulting	  lower	  than	  controls.	  	  Since	   it	  has	  been	  reported	   that	  TNF-α can modulate MMP-9 expression	  (34),	   we	   sought	   to	   analyse	   effects	   of	   TNF-­‐α	   antagonists	   on	   MMP-­‐9	  expression	  in	  PBMC.	  MMP-­‐9	  mRNA	  was	  increased	  in	  PBMC	  of	  psoriatic	  patients	  respect	  to	  healthy	  controls	  and	  anti-­‐TNF-­‐α	  treatment	  reduced	  these	  levels	  returning	  to	  normal	  values	  (P	  <	  0.001)	  (Fig.	  3).	  As	  for	  OPN,	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the	   2	   anti-­‐TNF-­‐α	   drugs	   induced	   a	   comparable	   decrease	   (data	   not	  shown).	   Difference	   in	   PBMC	   gene	   expression	   between	   T0	   and	   T1	   (Λ)	  was	   calculated	   in	  all	   subjects	   for	  OPN	   (Λ=0.31)	  and	  MMP-­‐9	   (Λ=0.44);	  no	  statistically	  significant	  difference	  was	  detected,	  suggesting	  a	  similar	  decreasing	  trend	  with	  anti-­‐TNF-­‐α	  treatment	  (Fig.	  4).	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Figure 1. OPN gene expression in PBMC  in healthy controls (Ctrl) and 
psoriatic patients before (T0) and after 24 weeks of therapy with anti-TNFα 
drugs (T1); P < 0.001 (***). 	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Figure 2. OPN plasmatic levels in healthy controls (Ctrl) and psoriatic 
patients before (T0) and after 24 weeks of therapy with anti-TNFα drugs 
(T1); P < 0.001 (***). 
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Figure 3. MMP-9 gene expression in PBMC in healthy controls (Ctrl) and  
psoriatic patients before (T0) and after 24 weeks of therapy with anti-TNFα 
drugs (T1); P < 0.001 (***). 	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Figure 4. Difference in PBMC gene expression of all psoriatic subjects 
between T0 and T1 for OPN and MMP-9. 
 
 
 
 
 16 
Conclusions 
 We	  have	  previously	  showed	  that	  OPN	  was	  increased	  in	  PBMC	  and	  skin	  samples	   of	   psoriatic	   subjects	   (31),	   whereas	   in	   the	   present	   study	   we	  have	   analysed	   the	   effect	   of anti-TNF-α therapy on OPN. In trying to 
understand if a change in OPN may be associated with TNF-α and involved 
in psoriasis pathogenesis, we focused our attention on its level in PBMC and 
in serum of psoriatic subjects where TNF-α is increased. TNF-α antagonists 
(etanercept and adalimumab) were able to decrease OPN either in PBMC or 
in plasma. A relationship between OPN and TNF-α has been previously 
assessed in tumour cell line in rat and human models, but not in psoriasis. 
Expression of OPN gene has been reported to be elevated by several factors, 
including TNF-α in ROS17/2.8 cells (rat osteosarcoma cells) (35) and in 
HN-22 cells (human head and neck squamous cell carcinoma cell line) (36). 
Our findings suggested a possible link between OPN and TNF-α in an 
inflammatory disease as psoriasis. This finding was supported by the fact 
that anti-TNF-α treatment was able to downregulate OPN. Consistent with 
this notion, OPN has been shown to be induced in other inflammatory 
conditions with TNF-α associated fibro-inflammatory process like human 
biliary atresia (37) and mice pulmonary fibrosis (38).  
Our findings showed that anti-TNF-α treatment reduced MMP-9 expression 
in PBMC of psoriatic patients. These data fitted to Cordiali-Fei et al who 
showed that therapeutic approaches based on anti-TNF-α were significantly 
associated to the decrease of serum levels of TNF-α, angiogenic molecules 
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and MMP-9 (34,25). MMP-9 contributes to the chronic inflammatory 
process in the skin of the psoriatic patients either directly, by sustaining the 
inflammatory process and the tissue distruction or indirectly, by allowing 
the traffic of inflammatory cells and enhancing the activity of inflammatory 
cytokines. Experimental evidences indicated that MMPs can mediate the 
proteolytic process leading to the release of the soluble, active molecule of 
TNF-α from a cell membrane-achored molecular form (39). In addition, due 
to its proteolytic activity, MMP-9 could contribute to the generation of 
immunogenic fragments of normal proteins that may offer the basis for the 
initiation of local autoimmune cellular responses. The inhibitory effect of 
anti-TNF-α therapy may thus offer a two-fold efficacy through the reduction 
of MMP-9 levels and the inhibition of processing of TNF-α precursor into 
its active molecular form. Our findings confirm the existence of a direct 
relationship between anti-TNF-α  therapy and decrease of MMP-9 
expression. 
Since it has been reported that OPN is a matricellular protein that plays an 
important role in tumour cell invasion due to its capacity to regulate the 
activity of at least two extracellular matrix degrading proteins: MMP-2 and 
urokinase plasminogen activator (40) and since it has been showed that 
OPN contributes to the increased amounts of MMP-9 in cardiac and skeletal 
muscle of mice (30), we wanted to analyse if there was a relationship 
between OPN and MMP-9 in psoriasis.	   A	   similar	   decreasing	   trend	   for	  OPN	   and	  MMP-­‐9	  was	   obtained	   by	   anti-­‐TNF-­‐α	   treatment,	   suggesting	   a	  possible	  link	  among	  the	  2	  molecules.	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For	   the	   wide	   spectrum	   of	   biological	   activities,	   different	   names	  have	  been	  assigned	  to	  OPN	  through	  time,	  indicating	  a	  role	  in	  processes	  that	  are	  not	  confined	  to	  bone	  development,	  remodeling,	  and	  resorption.	  In	  summary	  our	  findings	  showed	  that	  OPN and MMP-9 are increased in 
psoriasis and anti-TNF-­‐α	   treatment	   reduced	   them	   in	   a	   comparable	  fashion,	  so	  that	  we	  can	  hypothesize	  that	  they	  are	  involved	  in	  psoriasis	  pathogenesis.	   Our	   results	   suggest	   that	   OPN could be not only a key 
regulator of inflammatory processes of psoriasis, but also a biomarker for 
the efficacy of a treatment of this cutaneous disorder.	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